FluoGuide A/S (STO:FLUO)

Market Cap	551.62M
Revenue (ttm)	-820.40K
Net Income (ttm)	-47.96M
Shares Out	13.62M
EPS (ttm)	-3.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,002
Average Volume	10,111
Open	40.60
Previous Close	41.40
Day's Range	40.50 - 41.30
52-Week Range	29.10 - 57.00
Beta	0.87
RSI	45.56
Earnings Date	Nov 27, 2025

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUO

Financial Performance

In 2024, FluoGuide's revenue was 385,000, a decrease of -8.98% compared to the previous year's 423,000. Losses were -28.96 million, -24.54% less than in 2023.

Financial numbers in DKK